Neurocognitive Disorders

Introduction

Neurocognitive disorders represent a group of conditions characterized by a significant decline in cognitive functioning from a previously attained level. These impairments may affect multiple domains, including memory, attention, executive functioning, language, perceptual-motor abilities, and social cognition. According to the DSM-5-TR, neurocognitive disorders are broadly classified into delirium and major or mild neurocognitive disorders, depending on severity and impact on independence in everyday activities.

These disorders are typically caused by underlying neurological, medical, or substance-related conditions, and they often involve structural or functional changes in the brain. While neurocognitive disorders are most commonly observed in older adults due to neurodegenerative processes, they can also occur in younger individuals as a result of traumatic injury, infections, or genetic conditions. The course, severity, and reversibility of these disorders vary depending on the underlying etiology, making early diagnosis and appropriate intervention crucial for improving outcomes and quality of life.

Delirium

Introduction

Delirium is an acute and often reversible neurocognitive disorder characterized by a disturbance in attention, awareness, and cognition that develops over a short period of time. It is commonly seen in medical settings, particularly among hospitalized or elderly individuals, and is usually indicative of an underlying physiological disturbance.

Diagnostic Features

The core feature of delirium is a marked impairment in attention, which includes difficulty focusing, sustaining, or shifting attention. This is accompanied by reduced awareness of the environment and disturbances in cognition such as memory deficits, disorientation, language difficulties, or perceptual disturbances. A defining characteristic of delirium is its fluctuating course, with symptoms often worsening at night, a phenomenon sometimes referred to as “sundowning.” Individuals may appear confused, disorganized, and may exhibit altered levels of consciousness ranging from hyperalert agitation to lethargy. The acute onset and variability of symptoms distinguish delirium from other neurocognitive disorders.

DSM-5-TR Diagnostic Criteria

A. A disturbance in attention (i.e., reduced ability to direct, focus, sustain, and shift attention) and awareness.

B. The disturbance develops over a short period of time, represents a change from baseline attention and awareness, and tends to fluctuate in severity during the course of a day.

C. An additional disturbance in cognition (e.g., memory deficit, disorientation, language, visuospatial ability, or perception).

D. The disturbances in Criteria A and C are not better explained by another preexisting, established, or evolving neurocognitive disorder.

E. There is evidence from the history, physical examination, or laboratory findings that the disturbance is a direct physiological consequence of another medical condition, substance intoxication or withdrawal, or exposure to a toxin.

Etiology / Causes

The development of delirium is multifactorial and typically reflects a complex interaction between biological vulnerability and acute precipitating factors. From a biological perspective, delirium is associated with widespread disturbances in brain functioning, particularly involving neurotransmitter imbalances. Reduced cholinergic activity and increased dopaminergic activity are commonly implicated, leading to impaired attention and altered consciousness. Additionally, systemic conditions such as infections, metabolic imbalances, hypoxia, or organ failure can disrupt cerebral metabolism and neurotransmission, further contributing to the condition.

Environmental and clinical factors also play a significant role in precipitating delirium. Hospitalization, especially in intensive care units, often exposes individuals to sensory overload or deprivation, sleep disruption, and unfamiliar surroundings, all of which can impair orientation. Polypharmacy, particularly the use of sedatives, anticholinergics, or opioids, increases the risk, especially in older adults. Thus, delirium is best understood as a syndrome resulting from both underlying vulnerability and acute physiological stressors.

Risk and Prognostic Factors

Several predisposing and precipitating risk factors influence the likelihood and course of delirium. Advanced age is one of the most significant risk factors, as aging is associated with reduced cognitive reserve and increased susceptibility to physiological stress. Pre-existing neurocognitive disorders, sensory impairments such as vision or hearing loss, dehydration, and severe medical illnesses further increase vulnerability. Situational factors such as immobilization, lack of sleep, and unfamiliar environments also contribute significantly.

The prognosis of delirium depends largely on the prompt identification and management of its underlying cause. In many cases, delirium is reversible, particularly when precipitating factors are addressed early. However, it is associated with increased morbidity and mortality, prolonged hospital stays, and a higher risk of developing long-term cognitive decline. In vulnerable individuals, delirium may accelerate the progression of underlying neurodegenerative disorders.

Treatment

The treatment of delirium primarily involves identifying and addressing the underlying medical or physiological cause. This may include treating infections, correcting metabolic imbalances, discontinuing offending medications, or managing withdrawal states. A comprehensive medical evaluation is essential to determine the contributing factors and guide appropriate intervention.

Supportive care plays an equally important role in management. Ensuring adequate hydration, nutrition, and sleep is crucial, along with maintaining a calm and well-lit environment that promotes orientation. Reorientation strategies, such as clocks, calendars, and familiar objects, help reduce confusion. In cases of severe agitation or risk of harm, low-dose antipsychotic medications may be used cautiously, although non-pharmacological approaches are preferred whenever possible. Effective management requires a multidisciplinary approach involving medical, nursing, and psychological care.

Alzheimer’s Disease (Major Neurocognitive Disorder due to Alzheimer’s Disease)

Introduction

Alzheimer’s disease is the most common cause of major neurocognitive disorder and is characterized by a progressive decline in cognitive functioning, particularly memory. It is a neurodegenerative condition that typically begins insidiously and worsens over time, ultimately leading to severe impairment in daily functioning.

Diagnostic Features

The earliest and most prominent feature of Alzheimer’s disease is impairment in memory, especially the ability to learn and retain new information. As the disorder progresses, deficits extend to other cognitive domains, including language, executive functioning, and visuospatial abilities. Individuals may have difficulty finding words, solving problems, recognizing familiar people, or navigating their environment. Behavioral and psychological symptoms, such as apathy, irritability, and mood changes, are also common. The gradual and continuous decline in functioning is a hallmark feature of the disorder.

DSM-5-TR Diagnostic Criteria

A. Criteria are met for major neurocognitive disorder.

B. There is insidious onset and gradual progression of impairment in one or more cognitive domains.

C. For probable Alzheimer’s disease, either of the following:

1. Evidence of a causative genetic mutation, or
2. All three of the following:
   • Clear decline in memory and learning
   • Steadily progressive decline
   • No evidence of mixed etiology

D. The disturbance is not better explained by another disorder.

Etiology / Causes

Alzheimer’s disease is primarily associated with neurodegenerative changes in the brain, particularly the accumulation of beta-amyloid plaques and neurofibrillary tangles composed of tau protein. These pathological changes lead to neuronal damage, synaptic loss, and progressive brain atrophy, especially in regions responsible for memory and cognition such as the hippocampus. There is also a significant reduction in acetylcholine levels, a neurotransmitter critical for learning and memory processes.

Genetic factors play an important role, particularly in early-onset cases where specific gene mutations have been identified. In late-onset Alzheimer’s disease, genetic susceptibility interacts with environmental and lifestyle factors such as cardiovascular health, education level, and cognitive engagement. Chronic inflammation, oxidative stress, and vascular changes are also believed to contribute to disease progression, highlighting the multifactorial nature of its etiology.

Risk and Prognostic Factors

The most significant risk factor for Alzheimer’s disease is advancing age, with prevalence increasing dramatically in older populations. Family history and genetic predisposition, particularly certain alleles, increase susceptibility. Additional risk factors include cardiovascular disease, diabetes, low educational attainment, and lifestyle factors such as physical inactivity.

The prognosis of Alzheimer’s disease is progressive and irreversible, with symptoms worsening over time. The course typically spans several years, during which individuals gradually lose independence and require increasing levels of care. In advanced stages, individuals may become completely dependent and experience complications such as infections or malnutrition, which often contribute to mortality.

Treatment

There is currently no cure for Alzheimer’s disease, and treatment focuses on slowing progression and managing symptoms. Pharmacological treatments include cholinesterase inhibitors, which enhance cholinergic function, and NMDA receptor antagonists, which regulate glutamate activity. These medications may provide modest improvements in cognitive symptoms and delay functional decline.

Non-pharmacological interventions are equally important and include cognitive stimulation, structured routines, and environmental modifications to support daily functioning. Caregiver education and support are critical components of treatment, as caregiving can be physically and emotionally demanding. A multidisciplinary approach that addresses medical, psychological, and social needs is essential for improving quality of life.

Lewy Body Disease (Major Neurocognitive Disorder with Lewy Bodies)

Introduction

Lewy Body Disease is a progressive neurodegenerative disorder characterized by abnormal deposits of alpha-synuclein protein, known as Lewy bodies, within the brain. It represents one of the most common causes of major neurocognitive disorder after Alzheimer’s disease and is unique in that it shares clinical features with both Alzheimer’s disease and Parkinson’s disease. The condition is marked by a combination of cognitive decline, psychiatric symptoms, and motor abnormalities.

Diagnostic Features

The clinical presentation of Lewy Body Disease is distinctive due to the presence of fluctuating cognition, recurrent visual hallucinations, and parkinsonian motor symptoms. Cognitive functioning may vary significantly throughout the day, with periods of relative clarity alternating with confusion. Visual hallucinations are typically well-formed and detailed, often involving people or animals. Motor symptoms resemble those seen in Parkinson’s disease and include rigidity, bradykinesia, and postural instability. Individuals may also experience REM sleep behavior disorder, autonomic dysfunction, and heightened sensitivity to antipsychotic medications, which can worsen symptoms.

DSM-5-TR Diagnostic Criteria

A. Criteria are met for major neurocognitive disorder.

B. The disorder has an insidious onset and gradual progression.

C. The disorder meets criteria for probable or possible major neurocognitive disorder with Lewy bodies based on the presence of core clinical features, including fluctuating cognition, recurrent visual hallucinations, and spontaneous features of parkinsonism.

D. The disturbance is not better explained by another medical condition or mental disorder.

Etiology / Causes

Lewy Body Disease is associated with the abnormal accumulation of alpha-synuclein protein within neurons, forming Lewy bodies that disrupt normal cellular functioning. These deposits are found in both cortical and subcortical regions, leading to widespread impairment in cognitive, motor, and autonomic systems. Neurotransmitter dysfunction plays a central role, particularly involving dopamine and acetylcholine, which contributes to both cognitive deficits and motor symptoms.

The disorder reflects overlapping pathological processes seen in Alzheimer’s disease and Parkinson’s disease, which explains its mixed clinical presentation. Genetic factors may contribute to susceptibility, although most cases are sporadic. Additionally, neuroinflammatory processes and oxidative stress are believed to play a role in disease progression, further damaging neural structures and accelerating cognitive decline.

Risk and Prognostic Factors

Risk factors for Lewy Body Disease include advanced age, male gender, and a history of REM sleep behavior disorder. Genetic predisposition and overlapping neurodegenerative processes may also increase vulnerability. Individuals with pre-existing neurological conditions may be at higher risk of developing the disorder.

The prognosis is generally progressive, with symptoms worsening over time. The fluctuating nature of cognition can make management challenging, and individuals often experience a decline in both cognitive and motor functioning. Sensitivity to medications, particularly antipsychotics, can complicate treatment and increase the risk of adverse outcomes. Overall, the disease leads to significant impairment in daily functioning and reduced quality of life.

Treatment

The management of Lewy Body Disease focuses on symptom reduction and improving quality of life. Pharmacological treatment often includes cholinesterase inhibitors, which may help improve cognitive symptoms and reduce hallucinations by enhancing cholinergic functioning. However, the use of antipsychotic medications must be approached with extreme caution due to the risk of severe sensitivity reactions, including worsening of motor symptoms and confusion.

Non-pharmacological approaches are equally important and include structured routines, environmental modifications, and caregiver support. Managing sleep disturbances, ensuring safety, and addressing motor symptoms through physiotherapy can significantly improve daily functioning. A multidisciplinary approach involving neurologists, psychiatrists, and caregivers is essential for effective long-term management.

Vascular Disease (Major Neurocognitive Disorder due to Vascular Disease)

Introduction

Major neurocognitive disorder due to vascular disease results from impaired blood flow to the brain, leading to neuronal damage and cognitive decline. It is often associated with cerebrovascular events such as strokes or chronic small vessel disease and represents the second most common cause of dementia after Alzheimer’s disease.

Diagnostic Features

The cognitive profile of vascular neurocognitive disorder is characterized primarily by deficits in attention, executive functioning, and processing speed, rather than the prominent memory impairment seen in Alzheimer’s disease. Individuals may have difficulty planning, organizing, and making decisions, along with slowed thinking and reduced mental flexibility. The progression of symptoms is often described as “stepwise,” with sudden declines following vascular events. Neurological signs such as weakness, gait disturbances, or focal deficits may also be present, reflecting underlying cerebrovascular damage.

DSM-5-TR Diagnostic Criteria

A. Criteria are met for major neurocognitive disorder.

B. The clinical features are consistent with a vascular etiology, as suggested by either onset of cognitive deficits temporally related to a cerebrovascular event or evidence of decline in complex attention and executive function.

C. There is evidence of cerebrovascular disease from history, physical examination, or neuroimaging.

D. The disturbance is not better explained by another brain disease or systemic disorder.

Etiology / Causes

The primary cause of vascular neurocognitive disorder is reduced or disrupted blood flow to the brain, leading to ischemia and neuronal damage. This may occur due to large vessel strokes, small vessel disease, or chronic conditions that impair circulation. Repeated microinfarcts can accumulate over time, gradually affecting cognitive functioning.

Medical conditions such as hypertension, diabetes, hyperlipidemia, and atherosclerosis significantly contribute to vascular damage. Lifestyle factors, including smoking, poor diet, and physical inactivity, further increase risk. The interaction between vascular pathology and neurodegenerative processes can also occur, leading to mixed presentations that complicate diagnosis and treatment.

Risk and Prognostic Factors

Risk factors are largely related to cardiovascular health and include hypertension, diabetes, obesity, smoking, and sedentary lifestyle. Advanced age and a history of stroke or transient ischemic attacks further increase susceptibility. Socioeconomic factors and limited access to healthcare may also contribute to poor vascular health and increased risk.

The prognosis varies depending on the severity and frequency of vascular events. The course may be stepwise, with periods of stability followed by sudden decline. While some cognitive functions may stabilize with effective management of vascular risk factors, overall progression is common, and long-term impairment can be significant.

Treatment

Treatment focuses primarily on preventing further vascular damage by managing underlying risk factors. This includes controlling blood pressure, blood sugar, and cholesterol levels, as well as promoting healthy lifestyle changes such as regular exercise and smoking cessation.

Rehabilitation strategies, including cognitive therapy and occupational therapy, help individuals maintain independence and improve functioning. Supportive care and caregiver involvement are essential, as cognitive deficits may affect daily living. A comprehensive approach addressing both medical and cognitive aspects is necessary for optimal outcomes.

Traumatic Brain Injury (Major Neurocognitive Disorder due to Traumatic Brain Injury)

Introduction

Major neurocognitive disorder due to traumatic brain injury (TBI) occurs as a result of an external force causing damage to the brain. This may include head injuries from accidents, falls, sports, or violence, and can lead to both immediate and long-term cognitive impairment.

Diagnostic Features

Individuals with TBI-related neurocognitive disorder often present with deficits in attention, memory, executive functioning, and processing speed. They may also experience changes in personality, emotional regulation, and behavior, such as irritability, impulsivity, or apathy. The onset of cognitive impairment typically follows the injury, either immediately or after a brief recovery of consciousness. The severity of symptoms depends on the extent and location of brain damage.

DSM-5-TR Diagnostic Criteria

A. Evidence of traumatic brain injury with at least one of the following: loss of consciousness, post-traumatic amnesia, disorientation, or neurological signs.

B. The neurocognitive disorder presents immediately after the occurrence of the traumatic brain injury or after recovery of consciousness.

C. The cognitive deficits persist beyond the acute post-injury period.

Etiology / Causes

Traumatic brain injury results in structural and functional damage to brain tissue, including neuronal loss, axonal injury, and inflammation. The mechanical impact disrupts neural networks, leading to impairments in cognitive processing. Secondary injury processes, such as swelling, reduced blood flow, and neurochemical changes, can further exacerbate damage.

The severity, location, and frequency of injury play a crucial role in determining outcomes. Repeated injuries, such as those seen in contact sports, can lead to cumulative damage and increased risk of long-term neurocognitive impairment.

Risk and Prognostic Factors

Risk factors include involvement in high-risk activities such as contact sports, motor vehicle accidents, and occupations with physical hazards. Younger individuals may experience better recovery due to greater neuroplasticity, while severe injuries and repeated trauma are associated with poorer outcomes.

The prognosis varies widely depending on the severity of injury. Mild cases may show substantial recovery, while severe injuries can result in permanent cognitive deficits. Early intervention and rehabilitation significantly improve outcomes.

Treatment

Treatment involves a combination of medical management and rehabilitation. Acute care focuses on stabilizing the individual and preventing further injury. Long-term treatment includes cognitive rehabilitation, which aims to improve memory, attention, and executive functioning through structured exercises.

Psychological support is also essential to address emotional and behavioral changes. Multidisciplinary care involving neurologists, psychologists, and rehabilitation specialists helps optimize recovery and functional independence.

Parkinson’s Disease (Major Neurocognitive Disorder due to Parkinson’s Disease)

Introduction

Major neurocognitive disorder due to Parkinson’s disease occurs in individuals with an established diagnosis of Parkinson’s disease and involves a decline in cognitive functioning over time. While Parkinson’s disease is primarily known for its motor symptoms, cognitive impairment becomes increasingly prominent in later stages.

Diagnostic Features

The cognitive profile includes deficits in executive functioning, attention, and processing speed, along with difficulties in memory retrieval. Individuals may also experience visuospatial impairments and reduced mental flexibility. Unlike Alzheimer’s disease, memory problems are often less severe initially but become more pronounced as the disorder progresses. Behavioral changes, including apathy and depression, are also common.

DSM-5-TR Diagnostic Criteria

A. Criteria are met for major neurocognitive disorder.

B. The neurocognitive disorder has a gradual onset and progression in the context of established Parkinson’s disease.

C. The disturbance is not better explained by another disorder.

Etiology / Causes

The disorder is primarily caused by degeneration of dopaminergic neurons in the substantia nigra, which affects motor and cognitive circuits. As the disease progresses, other neurotransmitter systems, including acetylcholine, are also affected, contributing to cognitive decline.

Neurodegenerative processes spread to cortical regions, leading to broader cognitive impairment. The interaction between motor and cognitive systems highlights the complexity of the disorder.

Risk and Prognostic Factors

Longer duration of Parkinson’s disease and increased severity of motor symptoms are associated with a higher risk of cognitive decline. Older age and the presence of psychiatric symptoms also increase vulnerability.

The prognosis involves gradual progression, with increasing impairment in both motor and cognitive functioning, leading to reduced independence over time.

Treatment

Treatment includes optimization of dopaminergic medications to manage motor symptoms while minimizing cognitive side effects. Cholinesterase inhibitors may be used to address cognitive impairment.

Supportive care, including cognitive rehabilitation and caregiver support, plays a critical role in maintaining quality of life and functional independence.

Huntington’s Disease (Major Neurocognitive Disorder due to Huntington’s Disease)

Introduction

Huntington’s disease is a genetic neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. It is inherited in an autosomal dominant pattern and typically manifests in mid-adulthood.

Diagnostic Features

The disorder is marked by involuntary movements known as chorea, along with cognitive impairments in executive functioning, memory, and attention. Individuals often exhibit personality changes, irritability, depression, and impaired judgment. The progressive nature of the disease leads to significant functional decline.

DSM-5-TR Diagnostic Criteria

A. Criteria are met for major neurocognitive disorder.

B. There is evidence of Huntington’s disease based on genetic testing or family history.

C. The disturbance is not better explained by another disorder.

Etiology / Causes

Huntington’s disease is caused by a genetic mutation involving an expanded CAG repeat in a specific gene, leading to the production of an abnormal protein that accumulates in neurons and causes cell death. The degeneration primarily affects the basal ganglia, which are involved in motor control and cognitive functioning.

The progressive loss of neurons leads to widespread impairment in brain function, affecting both movement and cognition. The genetic nature of the disorder means that individuals with a family history are at significant risk.

Risk and Prognostic Factors

The primary risk factor is genetic inheritance, as the disorder follows an autosomal dominant pattern. Each child of an affected individual has a 50 percent chance of inheriting the mutation.

The prognosis is poor, as the disease is progressive and ultimately fatal. Symptoms worsen over time, leading to severe cognitive and physical impairment, with death typically occurring after several years of illness.

Treatment

There is no cure for Huntington’s disease, and treatment focuses on managing symptoms and improving quality of life. Medications may be used to control movement disorders and psychiatric symptoms.

Supportive care, including psychological support, physical therapy, and occupational therapy, is essential. Genetic counseling is also an important component for affected families, helping them understand the risks and implications of the disorder.